Dp antagonist
AssigneeOno Pharmaceutical Co., Ltd.
InventorsMasaki ASADA, Keisuke HANADA, Satonori HIGUCHI, Atsushi NAGANAWA, Yasuhiro TAKEDA
Life of this patent
Estimating the term…
Loading patent…
AssigneeOno Pharmaceutical Co., Ltd.
InventorsMasaki ASADA, Keisuke HANADA, Satonori HIGUCHI, Atsushi NAGANAWA, Yasuhiro TAKEDA
Estimating the term…
An object of the present invention is to provide a DP receptor antagonist. A compound represented by general formula (I): (wherein all symbols are as shown in the specification) and a pharmaceutically acceptable salt thereof have DP receptor antagonistic activity and are also highly safe, and thus are useful as active ingredients of pharmaceuticals for DP receptor-mediated diseases. In addition, the compound represented by the general formula (I) and the pharmaceutically acceptable salt thereof also have good transferability to the central nervous system, and thus are particularly useful as a preventive and/or therapeutic agent for diseases associated with DP receptors present in the central nervous system among DP receptor-mediated diseases, that is, sleep-wake disorders.
A compound represented by
A method for treating a DP receptor-mediated disease, comprising administering an effective amount of a compound that is {4-Chloro-3-[(2,6-dimethyl-4-{2-[(2R)-oxan-2-yl]ethoxy}benzene-1-carbothioyl)amino]phenyl}acetic acid or a pharmaceutically acceptable salt thereof to a patient in need of prevention and/or treatment of the DP receptor-mediated disease.
A method of antagonizing a DP receptor in a subject, comprising administering an effective amount of a compound that is {4-Chloro-3-[(2,6-dimethyl-4-{2-[(2R)-oxan-2-yl]ethoxy}benzene-1-carbothioyl)amino]phenyl}acetic acid or a pharmaceutically acceptable salt thereof to the subject.
Dependencies are inferred from the claim text.